TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05863494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders. Although tDCS is not currently FDA-approved it is considered a non-significant-risk therapy with no record of serious adverse effects.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS) sham
Description: TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders.~The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle.
Study: NCT05445011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide + TAA05 Cell Injection
Description: Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
Study: NCT04691063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316; Carboplatin; Etoposide；Radiotherapy
Description: SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palcebo; Carboplatin; Etoposide；Radiotherapy
Description: Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）
Study: NCT05491057

Intervention type: DRUG
Intervention: Neratinib
Description: Neratinib standard dose 240 mg once daily for 1 year
Study: NCT06212167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Interventions for Stroke Patient Care
Description: In the first phase of the research, the relatives of the patients who are in the hospital every day for a week during the routine and discharge process will be included in a training program. These trainings will be explained didactically to the caregiver at the bedside by the research supervisor and the intensive care nurse, the practices will be demonstrated with demonstrations, and the caregiver will be asked to apply them themselves. Then, the researchers will call the caregivers and make an appointment for an online meeting twice a week (7 weeks - 14 times). During these meetings, the training the caregivers need will be explained again and any questions they have will be answered. The researcher will also conduct motivational interviews with the caregivers.
Study: NCT05372380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1017-1
Description: Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose
Study: NCT06270693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic treatment
Description: Root canal treatment
Study: NCT05803889

Intervention type: OTHER
Intervention: Cardiac evaluation
Description: In order to obtain information on the body composition of the patients, a body composition measurement will be performed. A resting cardiac echocardiography will be performed to record myocardial deformations in a non-vulnerable way. A non-invasive evaluation of arterial function will be performed by ultrasound on the femoral artery during a standardized passive movement of the leg. An assessment of myocardial deformations will also be performed under submaximal exercise conditions (at a target heart rate of 120 beats per minute, low to moderate exercise intensity). All of these measurements will be performed during evaluation 1 and reproduced in the same way during the 4 other sessions planned during (evaluation 2, 3 and 4) and after the treatment (evaluation 5).

Intervention type: OTHER
Intervention: Cardiac evaluation
Description: The same measurements as the EC + Tax group will be performed but only once, at the end of the treatment.
Study: NCT05056454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online therapy with coaching within STAND
Description: Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or UCLA DGC's ParentMood course. The efficacy of each online course will be compared for equivalency.~Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical care within STAND
Description: Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider.

Intervention type: OTHER
Group type: OTHER
Intervention: Perinatal Psychiatric Care
Description: Perinatal psychiatric care involves medication management and supportive therapy for up to six months, with referrals to relevant community resources by the final visit.
Study: NCT04336397

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: multi-target stool DNA test
Description: Cluster randomized trial of high and medium intensity outreach with MT-sDNA compared with usual care

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: multi-target stool DNA test
Description: Cluster randomized trial of high and medium intensity outreach with MT-sDNA compared with usual care
Study: NCT04891991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal infliximab
Description: 1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: Standard pars plana vitrectomy
Study: NCT05372380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1017-2
Description: Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.
Study: NCT04891991

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pars plana vitrectomy
Description: Standard pars plana vitrectomy
Study: NCT05628181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational nudge intervention
Description: This project will adapt the EMPOWER educational brochure for PLWD receiving CNS polyRx. The educational brochure will be mailed to intervention participants identified through EHR at Michigan Medicine and Henry Ford Health System. The brochure will describe what CNS polyRx is, present information about the associated risks, and suggest that participants speak with the prescribing clinician or pharmacist about ways to potentially simplify the medication regimen. The tool will be adapted through three successive rounds of focus groups (AIM one of this project) of PLWD.
Study: NCT05865392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move physical activity support program
Description: The Move program includes four intervention components: 1) 3, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) access to an online fitness membership, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week. They will receive an online fitness center membership during this entire 12-week program.
Study: NCT06269354

Intervention type: DEVICE
Intervention: 3D printed prostheses
Description: 3D printed prostheses

Intervention type: DEVICE
Intervention: 3D printed prostheses
Description: 3D printed prostheses

Intervention type: DEVICE
Intervention: 3D printed prostheses
Description: 3D printed prostheses
Study: NCT05108116

Intervention type: DIAGNOSTIC_TEST
Intervention: EOS
Description: EOS Micro Dose imaging will be done. SterEOS 3D recontruction of the lower limb and pelvis will be performed.
Study: NCT05287503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol Hydrochloride
Description: Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients
Study: NCT05126004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetyl L Cysteine
Description: 28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
Study: NCT06442254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: In the application, which will be done with VR glasses, a video of walking on Istiklal Street in Istanbul's Beyoğlu district will be watched.
Study: NCT06628856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life
Description: The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life
Description: The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being.
Study: NCT05601882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets
Study: NCT04877587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~* 2 60 g/m2 IV Days (1,2,8,9,15,16)~* 1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~  * 1 30 g/m2 IV Days (1,2,8,9,15,16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
Study: NCT06123026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: 1mg oral cabergoline given to participants once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 encapsulated placebo tablet given to participants after procedure
Study: NCT05310708

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
Study: NCT05560555

Intervention type: DRUG
Intervention: Tafamidis
Description: 61 milligrams (mg) as received in studies B3461028 and B3461045
Study: NCT05975177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterify Gel
Description: A mucoadhesive polymeric hydrogel in a prefilled syringe for nonsurgical treatment of periodontal and peri-implant pockets, composed of polyvinyl polymers, hydroxytyrosol, nisin, and magnesium ascorbyl phosphate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.
Study: NCT06239714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-3403
Description: SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-3403
Description: SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-3403
Description: SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: The dosage of atorvastatin was determined by the investigator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: The dosage of atorvastatin was determined by the investigator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9%
Study: NCT05305768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IncobotulinumtoxinA
Description: Injection of glabellar rhytids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IncobotulinumtoxinA
Description: Injection of glabellar rhytids
Study: NCT04675775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically-tailored meals (MTM)
Description: After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplements
Description: A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education handout
Description: A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
Study: NCT05477719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing of specific compression stockings
Description: The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body
Study: NCT05601882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous Injection
Study: NCT06554080

Intervention type: PROCEDURE
Intervention: Platform-switched implant placement
Description: NobelParallel or NobelActive implants placed

Intervention type: PROCEDURE
Intervention: Platform-matched implant placement
Description: Nobel Brånemark, NobelSpeedy Groovy implants placed
Study: NCT06280157

Intervention type: BIOLOGICAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2

Intervention type: BIOLOGICAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2

Intervention type: BIOLOGICAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
Study: NCT06563518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meridol
Description: toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection
Description: toothpaste
Study: NCT04761562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet- and extracellular vesicle-rich plasma
Description: PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Edges of the tympanic membrane perforation will be refreshed and the tympanomeatal flap raised. Under the tympanic membrane perforation, a guide (fascia of the temporalis muscle, perichondrium, cartilage or fat) will be placed. An absorbent gelatin sponge will be placed under the guide and on the outer surface of the reconstructed tympanic membrane.
Study: NCT06430125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil 10 MG Oral Tablet
Description: Nicorandil 10 MG oral tablet twice daily
Study: NCT06414382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tape-stripping
Description: 22mm tapes x 40 will be attached and removed to skin of all for limbs (tape stripping). On left arm and leg skin will also be subject to micro needling.
Study: NCT06258980

Intervention type: DRUG
Intervention: Proph7
Description: Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females
Study: NCT06368752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GIP[3-30]NH2
Description: GIP\[3-30\]NH2 is the naturally occurring shorter (truncated) variant of GIP\[1-42\]. GIP\[3-30\]NH2 also stimulates the GIP receptor and therefore acts like a GIP receptorantagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium chlorid with 0,5% human serum albumin.
Study: NCT04880382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI treatment discontinuation
Description: After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
Study: NCT06413706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Administered orally or IV
Study: NCT04880382

Intervention type: DRUG
Group type: OTHER
Intervention: ICI treatment continuation
Description: After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity
Study: NCT05982249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Patients will be given earphones to hear a hypnotic script that was recorded by Dr. Zahi Arnon, a psychologist specializing in hypnosis after observing about ten BM examinations at the hematology institute. The length of the recording is about 7 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR)
Description: Patients will be connected to a VR device that will transmit to the patient's choice a 3D screen and soothing noise for about 7 minutes.
Study: NCT05678491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal band ligation
Description: The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
Study: NCT04846179

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Description: Patients recruited to Ginkgo Biloba Extract (GBE) group will be advised to take Webber Natural Ginkgo Biloba 120 mg soft gel, 1 tablet twice a day for 4 months.